NeuroBo Pharmaceuticals, Inc. (NRBO)
After hours:
- PR Newswire
NeuroBo Pharmaceuticals Appoints Joseph Hooker as Interim Chief Executive Officer and President
NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on therapies for cardiometabolic diseases, today announced that it has appointed Joseph Hooker as Interim Chief Executive Officer and President.
- PR Newswire
NEUROBO ANNOUNCES CLOSING OF $32.3 MILLION UNDERWRITTEN PUBLIC OFFERING INCLUDING FULL EXERCISE OF OVERALLOTMENT OPTION AND CONCURRENT PRIVATE PLACEMENT
NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO) ("NeuroBo" or the "Company"), a clinical-stage biotechnology company focused on therapies for cardiometabolic diseases, today announced the closing of an underwritten public offering of units with gross proceeds of approximately $17.3 million, which includes the full exercise of the underwriter's over-allotment option to purchase additional shares and warrants, prior to deducting underwriting discounts and commissions and offering expenses payable by
- PR Newswire
NEUROBO ANNOUNCES PRICING OF $30 MILLION UNDERWRITTEN PUBLIC OFFERING AND CONCURRENT PRIVATE PLACEMENT
NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) (the "Company" or "NeuroBo") today announced the pricing of an underwritten public offering of units and a concurrent private placement for gross proceeds of approximately $30 million prior to deducting underwriting discounts and commissions and offering expenses payable by NeuroBo.
